MRTX0902 (MRTX-0902) is a novel, potent, selective, brain-penetrant, and orally bioavailable SOS1 binder that disrupts the SOS1:KRASG12C PPI (protein-protein interaction) with a binding Ki of 1.9 nM and IC50 of 29 nM in MKN1 cells. Oral administration of MRTX0902 in combination with MRTX849 results in a significant increase in antitumor activity relative to that of either single agent, including tumor regressions in a subset of animals in the MIA PaCa-2 tumor mouse xenograft model. SOS1 is one of the major guanine nucleotide exchange factors that regulates the ability of KRAS to cycle through its 'on' and 'off' states. Disrupting the SOS1:KRASG12C protein–protein interaction (PPI) can increase the proportion of GDP-loaded KRASG12C, providing a strong mechanistic rationale for combining inhibitors of the SOS1:KRAS complex with inhibitors like MRTX849 that target GDP-loaded KRASG12C.

纯度：≥98%

CAS：2654743-22-1